Correlation Between Aileron Therapeutics and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aileron Therapeutics and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aileron Therapeutics and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aileron Therapeutics and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Aileron Therapeutics and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aileron Therapeutics with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aileron Therapeutics and Reviva Pharmaceuticals.

Diversification Opportunities for Aileron Therapeutics and Reviva Pharmaceuticals

-0.68
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Aileron and Reviva is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Aileron Therapeutics and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Aileron Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aileron Therapeutics are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Aileron Therapeutics i.e., Aileron Therapeutics and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Aileron Therapeutics and Reviva Pharmaceuticals

Given the investment horizon of 90 days Aileron Therapeutics is expected to generate 0.93 times more return on investment than Reviva Pharmaceuticals. However, Aileron Therapeutics is 1.08 times less risky than Reviva Pharmaceuticals. It trades about 0.18 of its potential returns per unit of risk. Reviva Pharmaceuticals Holdings is currently generating about 0.09 per unit of risk. If you would invest  187.00  in Aileron Therapeutics on October 22, 2024 and sell it today you would earn a total of  24.00  from holding Aileron Therapeutics or generate 12.83% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy68.42%
ValuesDaily Returns

Aileron Therapeutics  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Aileron Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Aileron Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Aileron Therapeutics and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aileron Therapeutics and Reviva Pharmaceuticals

The main advantage of trading using opposite Aileron Therapeutics and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aileron Therapeutics position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Aileron Therapeutics and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories